

Pathomics Health expands lab operations to Singapore

08 March 2022 | News

Focusing on Infectious Diseases and Oncology and hereby expanding its operations from Malaysia



Diagnostics and research service provider Pathomics Health has announced its laboratory operations expansion into Singapore. Qiagen will collaborate with Pathomics Health to expand innovative infectious diseases solutions for both research and clinical diagnostics in Singapore.

The Singapore laboratory of Pathomics Health will deliver clinical diagnostics services for infectious diseases, including QIAstat system for respiratory syndromic pathogens panel and gastrointestinal pathogens panel, QuantiFERON for latent tuberculosis diagnosis and high throughput QIASymphony workflow for other important infectious diseases.

In 2021, Pathomics Health was appointed by Qiagen as its preferred laboratory outsourcing next generation sequencing solutions partner for ASEAN markets.

Pathomics Health is also working closely with GenScript to offer clinical diagnostics services using cPass™ SARS-CoV-2 Neutralization Antibody Detection test that was jointly developed by GenScript and Duke NUS.

Image caption- Dr Tan Eng Lee (centre) and Qiagen Representatives – William Lin (left), Commercial Director of Korea & SEA and Eric Goh (right), Country Manager of Singapore & Malaysia.